Pascal Cathébras

Pascal Cathébras

Auto-generated profile, based on publicly available information

Pascal Cathébras

Service de médecine interne, hôpital Nord, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in La Presse Médicale
Verified
Journal Article
Closed access
PCPascal Cathébras
Pascal Cathébras
ABAurélie Begon
Aurélie Begon
SLSylvy Laporte
Sylvy Laporte
CBChristophe Bois
Christophe Bois
DTDidier Truchot
Didier Truchot

9 July 2014 in SpringerPlus
Verified
Journal Article
Open access
PDF file
ECEmilie Chalayer
Emilie Chalayer
MFMartine Ffrench
Martine Ffrench
PCPascal Cathébras
Pascal Cathébras
Peripheral cytopenias are common in systemic lupus erythematosus (SLE), but bone marrow involvement is rarely reported. Myelofibrosis is a rare disorder characterized by reticulin fibrosis of the bone marrow, which usually occurs in response to clonal proliferation of hematopoietic stem cells in myeloproliferative disorders. However, bone marrow fibrosis has also been described in association with auto-immune diseases, especially SLE. We will report here a new case of bone marrow fibrosis associated with SLE. We also reviewed the 27 cases published in the English language literature, and will discuss the clinical presentation, outcome, treatment, and pathophysiology of bone marrow fibrosis occurring in association with SLE. Over one half of patients were diagnosed concomitantly with bone marrow fibrosis and SLE. Epidemiological, clinical and biological features of lupus were unremarkable. Except for the presence of reticulin fibrosis, the findings from the bone marrow biopsies proved highly variable. Overall mortality was about 14% but corticosteroid-based therapy lead to clinical improvement and reverted bone marrow fibrosis in most cases. Data on the usefulness of other immunomodulatory therapies are inconclusive. SLE may be complicated by bone marrow involvement, of a likely autoimmune origin. Bone marrow fibrosis occurring with SLE is probably similar to “primary autoimmune myelofibrosis” and may respond to steroid and immunomodulatory therapies. Further studies with standardised proofreading of bone marrow aspirations and biopsies are needed to delineate the clinical and biological features of this rare complication of SLE.

14 March 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
VVVassili Valayannopoulos
Vassili Valayannopoulos
MSManuel Schiff
Manuel Schiff
NGNathalie Guffon
Nathalie Guffon
YNYann Nadjar
Yann Nadjar
AGAngels García-Cazorla
Angels García-Cazorla
FMFrancois Maillot
Francois Maillot
The Registry of Adult and Paediatric Patients Treated with Cystadane® – Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane®) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year. A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [≤18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 ± 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine β-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns. Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients.

1 December 2020 in Journal of Medical Mycology
Verified
Journal Article
Closed access
FSF. Schein
F. Schein
HMH. Munoz-Pons
H. Munoz-Pons
CMC. Mahinc
C. Mahinc
RGRémi GRANGE
Rémi GRANGE
PCP. Cathébras
P. Cathébras
PFP. Flori
P. Flori

1 March 2008 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
JGJ.-B. Gaultier
J.-B. Gaultier
AHA. Hot
A. Hot
PCP. Cathébras
P. Cathébras
CGC. Grange
C. Grange
JNJ. Ninet
J. Ninet
HRH. Rousset
H. Rousset

1 April 1993 in Social Science & Medicine
Verified
Journal Article
Closed access
JBJean Benoist
Jean Benoist
PCPascal Cathebras
Pascal Cathebras